- Home
- WSBF vs XFOR Comparison
WSBF vs XFOR Comparison
Compare WSBF & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSBF
- XFOR
- Stock Information
- Founded
- WSBF 1921
- XFOR 2014
- Country
- WSBF United States
- XFOR United States
- Employees
- WSBF N/A
- XFOR N/A
- Industry
- WSBF Savings Institutions
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WSBF Finance
- XFOR Health Care
- Exchange
- WSBF Nasdaq
- XFOR Nasdaq
- Market Cap
- WSBF 288.1M
- XFOR 332.3M
- IPO Year
- WSBF N/A
- XFOR N/A
- Fundamental
- Price
- WSBF $15.78
- XFOR $3.70
- Analyst Decision
- WSBF
- XFOR Strong Buy
- Analyst Count
- WSBF 0
- XFOR 3
- Target Price
- WSBF N/A
- XFOR $34.67
- AVG Volume (30 Days)
- WSBF 41.6K
- XFOR 612.3K
- Earning Date
- WSBF 10-23-2025
- XFOR 11-05-2025
- Dividend Yield
- WSBF 3.81%
- XFOR N/A
- EPS Growth
- WSBF 87.32
- XFOR N/A
- EPS
- WSBF 1.32
- XFOR N/A
- Revenue
- WSBF $137,060,000.00
- XFOR $33,979,000.00
- Revenue This Year
- WSBF N/A
- XFOR $1,307.51
- Revenue Next Year
- WSBF N/A
- XFOR N/A
- P/E Ratio
- WSBF $11.91
- XFOR N/A
- Revenue Growth
- WSBF 2.87
- XFOR 2925.74
- 52 Week Low
- WSBF $11.61
- XFOR $1.35
- 52 Week High
- WSBF $16.75
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- WSBF 59.58
- XFOR 51.95
- Support Level
- WSBF $15.11
- XFOR $3.49
- Resistance Level
- WSBF $15.98
- XFOR $3.90
- Average True Range (ATR)
- WSBF 0.29
- XFOR 0.23
- MACD
- WSBF 0.03
- XFOR -0.01
- Stochastic Oscillator
- WSBF 73.56
- XFOR 67.19
About WSBF Waterstone Financial Inc. (MD)
Waterstone Financial Inc is a holding company. Through its subsidiaries, it operates in two reportable segments: Community Banking and Mortgage Banking. The Community Banking segment provides consumer and business banking products and services to customers, which include various types of loans, deposits, and personal investment services. The Mortgage Banking segment involves residential mortgage loans for the primary purpose of sale in the secondary market. The vast majority of its revenue comes from the Community Banking segment.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.